<DOC>
	<DOCNO>NCT01829412</DOCNO>
	<brief_summary>Bone disease multiple myeloma ( MM ) routinely assessed skeletal X-ray ( XR ) magnetic resonance spine ( S-MRI ) . Diffusion-weighted MRI ( DW-MRI ) functional MRI detects water diffusion cell . This prospective phase II study compare whole-body DW-MRI XR S-MRI assessment MM bone lesion . METHODS . Thirty-six consecutive symptomatic patient diagnosis relapse perform XR , S-MRI , whole-body MRI , whole-body DW-MRI treatment , treatment , 6 month treatment . A substudy evaluate 12 asymptomatic patient diagnosis , 6 12 month . Radiology exams independently read 3 experienced radiologist , technique compare count segment focal lesion ( FL ) ( &gt; =5mm ) .</brief_summary>
	<brief_title>Whole Body Diffusion Weighted Magnetic Resonance Imaging ( DW-MRI ) Multiple Myeloma</brief_title>
	<detailed_description>PROTOCOL SYNOPSIS - Study Type Monocentric prospective clinical trial Study Object Comparison Whole Body Diffusion Weighted Magnetic Resonance Imaging ( DW-MRI ) skeletal X-Ray MRI spine assessment bone disease Multiple Myeloma ( MM ) Objectives Primary objective 1 ) To assess whether DW-MRI detect high number bone lesion standard X-Ray MRI spine Stage I-III symptomatic MM patient Secondary objective 1 . To assess whether change number lesion detect DW-MRI follow correlate disease response therapy 2 . To assess whether change number lesion detect DW-MRI follow correlate time re-treatment ( TTR ) 3 . To assess whether DW-MRI detect high number bone lesion Whole Body Magnetic Resonance Imaging ( WB-MRI ) Exploratory objective 1 ) To assess whether DW-MRI detect bone lesion standard X-Ray MRI spine Stage I asymptomatic MM patient diagnosis require treatment Study population design The study population consist consecutive Stage I-III ( Durie Salmon ) symptomatic Multiple Myeloma start first-line treatment relapse disease response ( CR PR ) last least 6 month . Study procedures The patient perform DW-MRI , whole body MRI ( WB-MRI ) , MRI spine plain skeletal X-Ray clinical laboratory evaluation follow timing : 1 . Patients first-line treatment MM : 1 . Within 15 day start treatment 2 . Within one month end first-line treatment 3 . 6 month end first-line treatment 2 . Patients relapse disease response ( CR PR ) last least 6 month 1 . At relapse 2 . Within 15 day end treatment relapse 3 . 6 month end treatment relapse The DW-MRI , WB-MRI MRI spine perform session . Each DW-MRI , WB-MRI , MRI spine skeletal X-Ray independently read interpreted two radiologist prove experience MM . Each radiologist read interpret exam perform ; lecture exam blind ; identity patient result lecture radiologist blind . In case number lesion detected radiologist would match , number lesion determine consensus radiologist . In case bone lesion detect DW-MRI compare MRI skeletal X-Ray , PET scan perform . Sample size The trial design demonstrate 30 % increase number bone lesion detect DW MRI ( experimental method ) compare standard X-Ray MRI spine ( standard method ) . To detect effect size one side Student test 5 % significance 90 % power , 27 patient need investigate , round 30 account 10 % patient drop . A midcourse sample size reassessment accord approach propose Proschan , Liu &amp; Hunsberger ( 2003 ) use interim data first 20 patient decide either maintain increase original sample size range 30 60 patient , depend whether estimate effect size align anticipated value . Substudy The substudy assessment exploratory objective enroll 10 consecutive Stage I ( Durie Salmon ) asymptomatic MM patient diagnosis require treatment . The patient perform radiological laboratory evaluation diagnosis 6 12 month diagnosis . Study duration The estimate duration enrolment range 15 30 month . The follow duration 6 month . The estimated total duration study 3 year . A midcourse assessment interim data plan end first phase enrolment ( 20 patient ) determine sample size second phase . Selection criterion Inclusion criterion - Age ≥18 year - Stage I-III ( Durie-Salmon ) symptomatic MM start first-line treatment relapse disease response ( CR PR ) last least 6 month - Stage I ( Durie-Salmon ) asymptomatic MM diagnosis require treatment ( substudy assessment exploratory objective ) - Written inform consent Exclusion criterion - Pregnancy lactation - Active secondary malignancy - Type I hypersensitivity anaphylactic reaction Gadolinum contrast agent - Mental disorder include claustrophobia ( ICD 10 , F40.2 ) - Electronically , magnetically mechanically activated implant - Ferromagnetic electrically operate active device like automatic cardioverter defibrillator - Cardiac pacemaker - Metallic splinter eye - Ferromagnetic haemostatic clip central nervous system ( CNS ) body - Cochlear implant stapedial implant - Insulin pump nerve stimulators - Prosthetic hearth valve Study Procedures baseline • Medical history physical examination - Cell blood count differential - Clinical laboratory evaluation : Na+ , K+ , Ca2+ , BUN , creatinine , LDH , PCRq , uric acid , AST , ALT , GGT , ALP , bilirubin ( total direct/indirect ) , albumin , protein electrophoresis , IgA , IgG , IgM , serum immunofixation , serum free light chain , 24h proteinuria , 24h Bence-Jones proteinuria , urine immunofixation , beta2microglobulin ; HIV-Ab , HBsAg , HCV-Ab ; pregnancy test female childbearing potential - ECG - DW-MRI ( whole body Diffusion Weighted Magnetic Resonance Imaging ) - WB-MRI ( Whole Body Magnetic Resonance Imaging ) - Skeletal survey include skull , cervical , thoracic lumbar spine , pelvis , right leave humerus femur , sternum bilateral rib - MRI spine - Bone marrow biopsy bone marrow aspirate morphology , FISH analysis del ( 13 ) , ( 4:14 ) , ( 11:14 ) , ( 14:16 ) , del ( 17 ) , flow cytometric immunophenotyping CD138+ , CD19+ , CD28+ CD117+ .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>• .Age ≥18 year , &lt; 80 year Stage IIII ( DurieSalmon ) symptomatic MM start firstline treatment relapse disease response ( CR PR ) last least 6 month Stage I ( DurieSalmon ) asymptomatic MM diagnosis require treatment ( substudy assessment exploratory objective ) Written informed consent Pregnancy lactation Active secondary malignancy Type I hypersensitivity anaphylactic reaction Gadolinum contrast agent Mental disorder include claustrophobia ( ICD 10 , F40.2 ) Electronically , magnetically mechanically activated implant Ferromagnetic electrically operate active device like automatic cardioverter defibrillator Cardiac pacemaker Metallic splinter eye Ferromagnetic haemostatic clip central nervous system ( CNS ) body Cochlear implant stapedial implant Insulin pump nerve stimulators Prosthetic hearth valve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>